key: cord-0991370-dqoh4vmf
authors: Jing, L.; Wu, X.; Krist, M. P.; Hsiang, T.-Y.; Campbell, V. L.; McClurkan, C. L.; Favors, S. M.; Hemingway, L. A.; Godornes, C.; Tong, D. Q.; Selke, S.; LeClair, A. C.; Pyo, C.-W.; Geraghty, D. E.; Laing, L. J.; Wald, A.; Gale, M.; Koelle, D. M.
title: T cell response to intact SARS-CoV-2 includes coronavirus cross-reactive and variant-specific components
date: 2022-01-25
journal: medRxiv : the preprint server for health sciences
DOI: 10.1101/2022.01.23.22269497
sha: 7e22db1819d8c6ba3214326e8a7ed7c37deb3eb4
doc_id: 991370
cord_uid: dqoh4vmf

SARS-CoV-2 provokes a brisk T cell response. Peptide-based studies exclude antigen processing and presentation biology and may influence T cell detection studies. To focus on responses to whole virus and complex antigens, we used intact SARS-CoV-2 and full-length proteins with DC to activate CD8 and CD4 T cells from convalescent persons. T cell receptor (TCR) sequencing showed partial repertoire preservation after expansion. Resultant CD8 T cells recognize SARS-CoV-2-infected respiratory cells, and CD4 T cells detect inactivated whole viral antigen. Specificity scans with proteome-covering protein/peptide arrays show that CD8 T cells are oligospecific per subject and that CD4 T cell breadth is higher. Some CD4 T cell lines enriched using SARS-CoV-2 cross-recognize whole seasonal coronavirus (sCoV) antigens, with protein, peptide, and HLA restriction validation. Conversely, recognition of some epitopes is eliminated for SARS-CoV-2 variants, including spike (S) epitopes in the alpha, beta, gamma, and delta variant lineages.

Introduction 9 cells (8, 11) . We observed robust TCL enrichment of virus-reactive CD4 T cells. For example, 151 participant W003 TCL had net 8.14% of cells responding to whole SARS-CoV-2 (Fig. 1C) , a 61-152 fold enrichment over the PBMC CD4 T cell AIM signal. Enrichment ranged from 41-to 201-fold 153 for the 5 subjects (Supplementary Table 2) . 154 155 Both monocytes in fresh PBMC and moDC can process and present antigens to CD4 T cells. 156 Higher levels of PBMC CD4 T cell activation were noted when autologous DC were used as 157 initial APC (Fig. 1B) compared to direct addition of killed virus to PBMC. Background signal for 158 mock antigen also slightly increased (median 0.16%, range 0.11%-0.47%). The median net 159

proportion of AIM (+) CD4 T cells was 0.66% (range 0.35% to 2.43%) across 12 samples. Use 160 of moDC allowed the sorting of a median of 11,320 activated CD4 T cells per specimen (range 161 8,190 to 19,860) , from which 20% were culture-expanded (Supplementary Table 2 ) and 80% 162 used for ex vivo TCR sequencing. 163

In addition to presentation to CD4 T cells, moDC can cross-present inactivated antigen to CD8 165 T cells. Using moDC, we observed specific CD8 T cell activation as measured by CD69 and 166 CD137 co-expression (Fig. 1B) . Negative control antigen was immunologically silent. We did not 167 detect PBMC CD8 T cell responses in HD ( Supplementary Fig. 2 ). As with CD4 T cells, higher 168 net proportions of AIM (+) CD8 T cells were noted with moDC (n = 12, median 0.95%, range 169 0.27 to 1.62%) than without (n = 5, median 0.033%, range 0.013%-0.29%) ( Supplementary Fig.  170 2B, Supplementary Table 2). A median of 842 CD8 T cells (range, 411 -2,611) were expanded 171 per specimen, while 80% of the AIM-sorted cell populations were TCR-sequenced. 172 173 Two subjects were studied using moDC at five time points each between 32 to 256 days after 174 recovery from COVID-19. Decreasing CD4 and CD8 AIM (+) abundance was noted over time 175 (Supplementary Table 2 ). Subject W005 had consistently higher CD4 than CD8 T cell 176 12 229 CD4 T cell responses to full-length SARS-CoV-2 proteins. expanded CD4 TCL, 230 enriched with or without DC boosting, were similarly tested proteome-wide. Each SARS-CoV-2 231 ORF or cleaved polypeptide product of ORFs polypeptide (PP)1a and PP1ab (29) Table 4) . 252 253 All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted January 25, 2022. ;

CD4 T cell epitopes. TCL initiated with several workflows were tested to define peptide 254 epitopes. Importantly, when TCL were started with peptide pools (as in Supplementary Fig. 5A) , 255 the resultant TCL recognized whole virus lysate and full-length protein ( Supplementary Fig. 5B ) 256 as well as peptides ( Supplementary Fig. 5C ), suggesting epitopes discovered with peptides are 257 relevant to viral infection. IFN-γ and proliferation readouts corresponded (representative data, 258

Supplementary Fig. 9 ) and we summarize epitopes defined with either ror both readouts. 259

Cultures initiated with complex antigen, such as from participant W001 using moDC-assisted 260 stimulation with whole virus, yielded multiple reactive peptides (representative data, 261

Supplementary Fig. 10 ). Overall, CD4 T cell epitopes were detected in 13 SARS-CoV-2 262 proteins. Responses were diverse within-person. For specimen 1 from participant W001 263 (Supplementary Table 1) , 55 epitopes were confirmed in 7 proteins, including 27 epitopes in S, 264 7 each in N and NSP3, 6 in ORF3A, 5 in M, 2 in ORF9B, and 1 in ORF7A (Supplementary 265   Table 5 ). Similarly, in participant W005 studied one month after recovery, 65 CD4 T cell 266 epitopes were identified in 10 proteins. Altogether, we observed 240 CD4 T cell peptide 267 reactivities from 8 persons (Supplementary Table 5 ). These correspond to 172 unique SARS-268

CoV-2 peptides (Supplementary Table 5 ). Amongst these, we found 70 epitopes in S protein, 26 269 in N protein, and 23 in M protein, with fewer in ORFs 3A, 7A, 8, and 9, and NSPs 1, 2, 3, 4, 6, 270 and 7. Peptides with CD4 T cell recognition by at least half the population studied included M 271 -81, M 177-189, S aa 133-145, S 165-177, N 289-301, and N 349-361. 272 273 CD4 T cell HLA restriction and functional avidity. Studies of CD4 T cell HLA restriction and 274 estimated functional avidity (representative data, Supplementary Fig. 11 ) yielded HLA locus-275 level data on 118 of 123 (96%) peptides tested. Amongst these, 84 (72%) were HLA DR-276 restricted, 23 (20%) were HLA DQ-restricted, and 11 (8%) were HLA DP-restricted 277 (Supplementary Table 5 ). HLA restriction at the locus level was generally identical if two 278 participants recognized the same peptide, but there were exceptions. S protein aa 165-177 was 279 14 HLA DP-restricted in 4 participants and HLA DR-restricted in 2. Allele-level restriction was 280 determined using aAPC (representative data, Supplementary Fig. 11A, 11B ). We observed 281 presentation by 10 distinct HLA DRB1, DRB3, and DRB4 alleles (Supplementary Table 5) . 282

Some peptides in SARS-CoV-2 S, M, and N proteins were presented by both DRB1 and either 283 DRB3 or DRB4 (representative data, Supplementary Fig. 11C ) or dual DRB3 alleles (not 284 shown). Functional avidity data were available for 124 CD4 T cell epitopes (representative data, 285

Supplementary Fig. 11 , summarized in Supplemental Table 5 ). Responses at 1 and 10 ng/ml 286 peptide were noted for 4 and 10 epitopes, respectively. S 165-177 was particularly potent, with 287 responses at 1 or 10 ng/ml for 5 of 6 subjects. 288

Recognition of seasonal coronaviruses. Cross-recognition of SARS-CoV-2 and sCoV 290 peptide has been documented (6, 20), but less is known about recognition of complex viral 291 antigens. We found that polyclonal CD4 TCL each of three subjects studied, enriched from 292 PBMC using whole SARS-CoV-2 antigen and moDC, cross-recognized either whole OC43 or 293 whole 229E cell-associated virus (Fig. 5A ). Control mock-infected virus preparations were 294

negative. An additional CD4 TCL enriched using whole SARS-CoV-2 antigen without moDC 295 also cross-recognized OC43. For subject W001, S proteins from both viruses were both 296 antigenic ( Fig. 5B ), as were both homologs of a peptide in S. The HLA restricting allele was 297 established as HLA DRB1*15:01 (Fig. 5C ). Cross-recognition of an HLA DP-restricted peptide 298 that is nearly identical in SARS-CoV-2, OC43, and HKU1 N proteins was also observed 299 ( Supplementary Fig. 12) . 300 301

CoV-2 T cell epitopes detected using Wu- 14-17). In addition to loss of recognition of variant aa in B.1.1.7 (effects summarized in Table 1  320 and Fig. 7 ) and/or P.1 lineages, we also noted strain-specific recognition of B.1.1.7-associated 321 sequences that were already prevalent in early 2020 and not unique to VBM (example, The T cell response to SARS-CoV-2 is functionally important (31). Studies have correlated T 328 cell kinetics, magnitude or phenotypes with disease in apparently immune competent persons 329 with delayed or dis-coordinated immunity and poor clinical outcome (8, 32). T cell responses 330 have been linked to protection from re-infection (33). Disease states and iatrogenic treatments 331 that decrease T cell responses can prolong live virus shedding (34, 35) . Cooperation between T 332 and B cells, such as antigen-specific CD4 TFH (36), also suggest that T cells are involved in 333 pathogen control. Supporting this, S-specific CD4 T cell TCR breadth and depth correlate with 334 nAb titers in COVID-19 convalescent persons (9). CD8 T cell depletion data in non-human 335 primates indicate that these effectors contribute to vaccine-induced protection (3). 336

Many groups have detected responses to SARS-CoV-2 epitopes using peptide-based 338 technologies (31), but less work has focused on T cell reactivity to complex antigens such as 339 whole virus or full-length proteins. Both T cell priming, and effector responses of memory T 340 cells, occur in vivo in the context of viral infection and/or loading of antigen into various APC, 341 with important differences for HLA class I and II (37). In the present report, we leveraged the 342 ability of moDC to cross-present whole viral antigen to CD8 T cells, and to present viral antigen 343 to CD4 T cells, to enrich polyclonal SARS-CoV-2-specific T cells. Similar studies are rare; in one 344 report, live virus induced subtle IFN-γ expression in convalescent T cells, but confirmation of 345 virus specificity was not documented (38). Using established (25, 30, 39-42) readout methods, 346 TCL created after whole virus or simpler antigen stimulation were used to study the breadth and 347 specificity of the T cell response, reactivity to virus-infected cells, and recognition of sCoV and 348 SARS-CoV-2 variants. 349 350 All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted January 25, 2022. ;

Acute COVID-19 most severely effects the respiratory tract, and while autopsy surveys can 351 detect virus body-wide (43), it is likely that T cell contributions to host defense and possibly to 352 inflammatory damage occur mostly in the respiratory tract and draining lymph nodes. Cytotoxic We studied T cell responses from relatively few persons and have not attempted to evaluate 379 novelty per-epitope given the plethora of work in this area. Coverage of the entire viral 380 proteome may, however, enable some novel insights. Mass spectroscopy suggests a large 381 spectrum in SARS-CoV-2 NSP abundance in infected cell cultures (54, 55) and in vivo (56, 57) . 382

Previous studies suggesting that viral protein abundance is associated with CD4 T cell 383 immunodominance (39, 58) are supported by our finding of prevalent and poly-specific 384 responses to the abundant S and N proteins. The high population prevalence of CD4 responses 385 to M, NSP3 and ORF3A also agree with prior work (31). We also found responses to NSP2 and 386 ORF9B in at least half the subjects studied proteome-wide. NSP2 has previously been 387 described as a CD4 immunogen in convalescent persons, while ORF9B was not included in 388 some previous surveys (4, 11, 59-62). ORF9B is an alternative open reading frame within the 389 nucleoprotein locus encoding a 98 aa-long ORF9B protein that is abundant in infected cells 390 (54), localizes to mitochondria (63), elicits strong antibody responses (64), and is involved in 391 evasion of type I IFN responses (65). CD4 T cell breadth was studied in 17 samples from 8 392 persons. We found a median CD4 breadth of 7 viral antigens/specimen, and that 6 of 8 persons 393 recognized 7 or more proteins. In contrast, a survey of 99 convalescent persons with proteome-394 wide peptides and an ex vivo AIM approach found an average of 3.2 CD4 T cell antigenic 395 proteins per person with no subject recognizing over 6 proteins (4). 396 397 TCL allowed tests of a large number of SARS-CoV-2 variant peptides. We found many 398 examples of abrogation or reduction of recognition of variants, some from variants of concern. 399 The literature consensus is that T cell responses to infection or vaccination are poly-specific, 400 such that failed variant epitope recognition may not have a net deleterious effect on immunity 401 The present report also adds to the growing body of literature concerning cross-recognition of 424 sCoV and SARS-CoV-2 (20, 27, 74-76). The use of whole viral antigens in both stimulation and 425 readout stages of our investigations of sCoV allowed us to document that polyclonal CD4 TCL 426 from COVID-19 convalescent persons can recognize whole OC43 and 229E viral antigen. As 427 All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted January 25, 2022. ; https://doi.org/10.1101/2022.01.23.22269497 doi: medRxiv preprint 20 mentioned above, this assay format integrates antigen processing and presentation to 428 supplement studies that focus solely on peptide reactivity. Validation to the antigen, peptide, 429 and HLA restriction level was obtained for an epitope in OC43 S. The presence and sequencing 430 of SARS-CoV-2 and sCoV infections in our study population are unknown. However, the timing 431 of our specimen collection shortly after recovery from COVID-19, and sero-epidemiologic data 432 that most adults have been infected with multiple sCoV, suggest the T cell cross-reactivities we 433 detected may reflect prior sCoV infections boosted by SARS-CoV-2, Data concerning sCoV T 434 cell cross-reactivity can be integrated with antibody-based (77, 78) and clinical studies (79) The current study has limitations. We observed no AIM response to whole SARS-CoV-2 in HD, 439 yet, several groups have documented the presence of SARS-CoV-2-reactive T cells in 440 uninfected individuals from either the naïve or sCoV-primed memory repertoires (20, 80). Our 441 approaches may be better suited to memory response to SARS-CoV-2 infection itself but could 442 be adapted to capture these responses, for example by using higher input cell numbers. We 443 noted only moderate preservation of TCR sequences comparing ex vivo sorted AIM (+) T cells 444 and expanded cultures. Biological factors related to TCR repertoire differences could include 445 rare clonotypes that assorted into either the ex vivo TCRseq or expansion fractions of the AIM 446 (+) cells, rather than being represented in both. Indeed, sequencing of AIM (+) cells ex vivo 447 shows broad and diverse responses at the TCR sequence level even to single epitopes, with 448 many clonotypes detected at low levels (81). T cell programming could render some T cells 449 refractory to expansion, with an exhausted T cell phenotype noted for SARS-CoV-2-specific 450 memory T cells in some settings (82). Technical factors could also contribute, ranging from DNA 451 extraction or PCR inefficiencies during TCR sequencing protocols to lack of provision of T cell 452 expansion culture conditions required for some of the AIM (+) cells. Analytically, we discounted 453 All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted January 25, 2022. ;

T cell clonotypes detected at less than two copies, potentially reducing concurrency between ex 454 vivo and expanded repertoires. Alternative methods such as single-cell TCRseq (83) to capture 455 the TCR repertoire AIM (+) cells ex vivo can be applied in the future to study the virus-specific 456 repertoire before and after expansion and to determine if there are transcriptional programs 457 correlated with failure to expand. In addition, a relatively low number of persons were studied. 458

The viral antigens used could have low abundance for some viral proteins in our antigen 459 preparation, leading to underestimation of antigen breadth. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Subjects and specimens. The COVID-19 cohort has been described (7-10). Subjects 473

reporting SARS-CoV-2 detection and an illness compatible with COVID-19 were recruited. 474

Subjects were seropositive for serum IgG for SARS-CoV-2 S and nucleoprotein (N) (7) 475 (Supplementary Table 1 (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted January 25, 2022. ;

(Expressway, ThermoFisher). SARS-CoV-2 S Wu-1 with the D614G mutation, 497

HDM_Spikedelta21_D614G (Addgene #158762), and isogenic mutant K417N are described 498 (86, 87). Additional plasmids were designed per S consensus data (22) (88) were tested at 1:1000. 519 520 All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted January 25, 2022. ; https://doi.org/10. 1101 /2022 Peptides covering the SARS-CoV-2 strain Wu-1 predicted proteome, 13 aa long overlapping by 521 9 aa, were obtained at ≥70% purity (Genscript, Piscataway, NJ) and dissolved at 20 mg/ml in 522 DMSO (ThermoFisher). Peptides in SARS-CoV-2 ORFs polypeptides PP1a and PP1ab are 523 numbered by positions in the polypeptide rather than within non-structural proteins (NSPs). 524

Pools contained ≤ 54 peptides, maintaining 1 μg/ml final in-assay concentrations each, and ≤ 525 0.3% DMSO. Selected peptides containing variant aa, peptides shorter than 13 aa predicted to 526 bind to HLA class I alleles, or peptides internal to antigenic peptides were also studied. Variants (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted January 25, 2022. ; https://doi.org/10.1101/2022.01.23.22269497 doi: medRxiv preprint (Becton Dickinson, 4B4-1), and 7-actinomycin D (7-AAD). Live CD3 + CD4 + CD8or CD4 -CD8 + 547 cells with CD137 and CD69 expression were bulk-sorted and 20% of sorted cells were non-548 specifically expanded for two cycles (94), with 80% saved for TCR sequencing. moDC were 549 also used to present single viral proteins. HeLa cells (CCL-2, ATCC) were transfected with 550 SARS-CoV-2 genes cloned into pDEST103, or pDEST103 control, using FuGene 6 (Promega) 551 and collected at 48 hours. Transfected cells were suspended to 1 x 10 6 cells/ml and UV-C-552 treated in a 6-well plate with 3600 μJ/cm 2 . moDC were collected at day 7 with EDTA and 1 x 10 5 553 moDC in 0.4 ml TCM were seeded into 48-well plates for 4 hours prior to adding 1 x 10 5 UV-554 treated HeLa for one hour. 1.5 x 10 6 autologous PBMC in 0.1 ml were added at 37°C for 18 555 hours. AIM sorting was also used after stimulation of PBMC without moDC addition. (ThermoFisher) and cultured at 4 x 10 6 /well in 24-well plates in 2 ml (TCM) (25) for 5 days with 566 SARS-CoV-2 peptide pools (≤ 54 peptides/pool, 1 μg/ml final each) covering S (6 pools), M (one 567 pool), N (two pools), or NSP6 and E proteins (2 pools). After staining with anti-CD3-PE, anti-568 CD4-APC (ThermoFisher, S3.5), anti-CD8-FITC, and 7-AAD for viability, live CD3 + CTV low cells 569 with CD4 -CD8 + or CD4 + CD8phenotype were bulk-sorted (FACSARIA II, Becton Dickinson). 570

Polyclonal CTV low T cell lines were expanded twice polyclonally (94). 571 572 All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted January 25, 2022. ; https://doi.org/10.1101/2022.01.23.22269497 doi: medRxiv preprint Tetramer sorting. Monomeric HLA-β2M complexes with UV-labile peptide (BioLegend) were 573 used for UV peptide exchange and tetramerized with streptavidin-APC or streptavidin-PE 574 (Becton Dickinson) per the manufacturer. Bulk-expanded CD8 T cells (~10 6 ) were stained in 575 100 μl TCM with 2 μl tetramer for 30 minutes on ice, followed by anti-CD4-APC-H7 and anti-576

CD8α-FITC. After 7-AAD staining, live CD8 + CD4tetramer high cells were sorted, expanded (94) (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Peptides at 1 μg/ml each final concentration were added as pools or singletons in ≤0.3% 636 DMSO, or DMSO negative control. After 1 to 2 days, supernatant IFN-γ was measured by 637 ELISA. For some assays with high IFN-γ ELISA OD450 values for negative control stimuli, ELISA 638 was performed with diluted supernatants. In order for a peptide to be reported as an epitope, 639 two or more wells tested with 1 μg/ml peptide were required to have an IFN-γ OD450 at least 640 twice above DMSO background in at least two assays. For proliferation assays, peptides (1 641 μg/ml) were tested using autologous EBV-LCL (1 X 10 4 /well, irradiated 10,000 rad) and 642 responder TCL (5 X 10 4 /well) in duplicate. For a peptide to be reported as an epitope, both 643

replicates had a count per minute (CPM) value more than 2-fold the average CPM of DMSO 644 negative controls, and, in follow-up triplicate screens, at least two of the three CPM values were 645 more than 2-fold average CPM of negative controls. To enumerate CD4 T cell reactivities per-646 subject, each reactive peptide was counted as a separate epitope. If two variant SARS-CoV-2 647 peptides were reactive for the same person, this was counted as one reactivity. Reactivities 648 detected in more than one workflow or PBMC timepoint per person are counted once. 649 All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted January 25, 2022. ; https://doi.org/10.1101 https://doi.org/10. /2022 Responses to the same or variant peptides in multiple participants were analyzed both 650 separately and after collapse to unique peptides. 651

We defined CD4 TCL HLA restriction as published (40). First, serial dilutions of peptide (1, 0.1, 653 or 0.01 μg/ml) were tested in triplicate using autologous EBV-LCL as APC without or with mAbs 654 that block HLA DR, DP, or DQ (100). To determine allele-level restriction, engineered APC 655 expressing single HLA class II heterodimers were selected (40) to match the study subject. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted January 25, 2022. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted January 25, 2022. ; https://doi.org/10.1101/2022.01.23.22269497 doi: medRxiv preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted January 25, 2022. ; https://doi.org/10.1101 https://doi.org/10. /2022 A*02:01 and treated with wild-type but not variant peptides were recognized by polyclonal CD8 757 TCL lines. Lineage B.1.351 is also known as beta and P.1 is also known as gamma). 758 759 All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted January 25, 2022. ; monitored, VOC = variants of concern per US CDC October 2021. 765 All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted January 25, 2022. ; https://doi.org/10.1101/2022.01.23.22269497 doi: medRxiv preprint 37 766 All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Gating scheme at top. Lower panels show expression of activation markers CD137 and CD69 in response to 18 hour stimulation amongst CD4 or CD8 T cells. B: Similar layout for subject W005, specimen 1 PBMC stimulated with autologous moDC pre-treated with SARS-CoV-2 or mock antigen. Gating scheme at top. For both stimulation methods, numbers are percentages of gated T cells expressing dual activation markers. C: CD69/CD137 positive CD4 T cells from the pathway in part A: were expanded and tested for reactivity with inactivated cell-associated SARS-CoV-2 or mock antigen. Gated, live, responder, CD3+/CD4+/CD8-cells are shown. Numbers are percent of cells accumulating the indicated cytokines. (+) proteins 2 4 4 3 3 0 2 1 1 0 1 3 1 2 0 8 5 0 0 7 1 4 0 3 6 7 0 0 (+) subjects CD4 SARS-CoV-2 proteome-wide screens CD4 TCL from PBMC stimulated with moDC and whole SARS-CoV-2 (subjects W001, W005, W012) or PBMC stimulated with whole SARS-CoV-2 (subject W003) recognize whole SARS-CoV-2, and sCoV OC43 or 229E antigens (V), but not mock (M) antigens. B: CD4 TCL from subject W001 recognizes full-length S protein from OC43 but not empty vector control. C: CD4 TCL recognize homologous S peptides from SARS-CoV-2 and OC43 in an HLA DR-restricted fashion as indicated by inhibition with locus-specific mAb. An overlapping SARS-CoV-2 peptide shows DRB1*15:01 restriction at right. Conserved AA are underlined. peptides. aAPC transfected with HLA A*02:01 and treated with wild-type but not variant peptides were recognized by polyclonal CD8 TCL lines. Lineage B.1.351 is also known as beta and P.1 is also known as gamma). 

DRB1*03:01 in one subject, DR locus in 2nd subject

Responses in one subject DRB1*07:01 restricted; in 2nd subject restricted by both alleles shown; significantly reduced recognition 707 of variant for both subjects using autologous EBV-LCL as APC

Assessment of protection 769 against reinfection with SARS-CoV-2 among 4 million PCR-tested individuals in Denmark in 2020: 770 a population-level observational study

Messenger RNA vaccines against SARS-CoV-2

Correlates of 773 protection against SARS-CoV-2 in rhesus macaques

Comprehensive analysis of T cell 775 immunodominance and immunoprevalence of SARS-CoV-2 epitopes in COVID-19 cases

Magnitude and 778 Dynamics of the T-Cell Response to SARS-CoV-2 Infection at Both Individual and Population 779 Levels. medRxiv

SARS-CoV-2-reactive T cells in 781 healthy donors and patients with COVID-19

Clinical, 783 laboratory, and temporal predictors of neutralizing antibodies against SARS-CoV-2 among 784 COVID-19 convalescent plasma donor candidates

T-cell 789 receptor sequencing identifies prior SARS-CoV-2 infection and correlates with neutralizing 790 antibody titers and disease severity. medRxiv : the preprint server for health sciences

CoV-2 specific B-cell epitopes and validation in ELISA for serological diagnosis of COVID-19. 794 Scientific reports

Targets of T Cell 796 Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and Unexposed 797 Individuals

CoV-2 assessed for up to eight months after infection. bioRxiv : the preprint server for biology

Broad cross-802 reactive TCR repertoires recognizing dissimilar Epstein-Barr and influenza A virus epitopes

Enhanced influenza A 805 H1N1 T cell epitope recognition and cross-reactivity to protein-O-mannosyltransferase 1 in 806 Pandemrix-associated narcolepsy type 1

Global analysis of shared 808 T cell specificities in human non-small cell lung cancer enables HLA inference and antigen 809 discovery

Magnitude of Off-Target Allo-HLA Reactivity by Third-Party Donor-Derived Virus-Specific T Cells 812 Is Dictated by HLA-Restriction

CD8(+) 821 T cells specific for an immunodominant SARS-CoV-2 nucleocapsid epitope cross-react with 822 selective seasonal coronaviruses

Recurrent 824 deletions in the SARS-CoV-2 spike glycoprotein drive antibody escape

Emergence of a 827 SARS-CoV-2 variant of concern with mutations in spike glycoprotein

Nextstrain: real-time 829 tracking of pathogen evolution

The Global 831 Phosphorylation Landscape of SARS-CoV-2 Infection

Genome-Wide Approach 833 to the CD4 T-Cell Response to Human Herpesvirus 6B

Unbiased Screens 837 Show CD8(+) T Cells of COVID-19 Patients Recognize Shared Epitopes in SARS-CoV-2 that Largely 838 Reside outside the Spike Protein

Prevalent and Diverse 840 Intratumoral Oncoprotein-Specific CD8(+) T Cells within Polyomavirus-Driven Merkel Cell 841

Flexible 843 Collection of SARS-CoV-2 Coding Regions. G3 (Bethesda, Md)

Herpes 846 simplex virus type 1 T-cells antigens in humans revealed by cross-presentation and genome-847 wide screening

Adaptive immunity to SARS-CoV-2 and COVID-19

Highly functional virus-specific 851 cellular immune response in asymptomatic SARS-CoV-2 infection

SARS-CoV-2 853 responsive T cell numbers and anti-Spike IgG levels are both associated with protection from 854 COVID-19: A prospective cohort study in keyworkers

CoV-2 infectiousness among three immunocompromised patients: from prolonged viral 860 shedding to SARS-CoV-2 superinfection. The Journal of infectious diseases

SARS-CoV-862 2 induces robust germinal center CD4 T follicular helper cell responses in rhesus macaques. 863 Nature communications

Pathways of antigen processing. Annual review of 865 immunology

867 Detection of IFNgamma-Secreting CD4(+) and CD8(+) Memory T Cells in COVID-19 Convalescents 868 after Stimulation of Peripheral Blood Mononuclear Cells with Live SARS-CoV-2

CD4 T-cell memory 871 responses to viral infections of humans show pronounced immunodominance independent of 872 duration or viral persistence

Proteome-Wide Zika Virus 874 CD4 T Cell Epitope and HLA Restriction Determination

Identification of novel 876 Mycobacterium tuberculosis CD4 T-cell antigens via high throughput proteome screening

Zoster vaccination increases 879 the breadth of CD4+ T cells responsive to varicella zoster virus. The Journal of infectious 880 diseases

Human kidney is a target for novel 882 severe acute respiratory syndrome coronavirus 2 infection

Disrupts Bidirectional Nucleocytoplasmic Transport through Interactions with Rae1 and Nup98. 886 mBio

Characterizing Viral 888 Infection by Electron Microscopy: Lessons from the Coronavirus Disease 2019 Pandemic. The 889 American journal of pathology

Ciliary Functionality of Different Airway Epithelial Cell Lines in Three-Dimensional Cell Culture

Nasal ciliated cells are primary targets for 894 SARS-CoV-2 replication in the early stage of COVID-19

The ORF8 protein of SARS-CoV-2 mediates 897 immune evasion through down-regulating MHC-Ι. Proceedings of the National Academy of 898 Sciences of the United States of America

Recruitment of highly functional SARS-CoV-2-specific CD8+ T cell receptors 900 mediating cytotoxicity of virus-infected target cells in non-severe COVID-19

Herpes simplex virus 902 infection of human fibroblasts and keratinocytes inhibits recognition by cloned CD8+ cytotoxic T 903 lymphocytes

Expansion of Cytotoxic 905 CD4+ T cells in the lungs in severe COVID-19. medRxiv. 2021. 906 52

Broad Severe Acute 910 Respiratory Syndrome Coronavirus 2 Cell Tropism and Immunopathology in Lung Tissues From 911 Fatal Coronavirus Disease 2019. The Journal of infectious diseases

Proteomics of SARS-CoV-2-913 infected host cells reveals therapy targets

Characterisation of the transcriptome and proteome of SARS-CoV-2 reveals a cell passage 916 induced in-frame deletion of the furin-like cleavage site from the spike glycoprotein. Genome 917 medicine

Mass-Spectrometric Detection of SARS-CoV-2 Virus in Scrapings of the Epithelium of the 923 Nasopharynx of Infected Patients via Nucleocapsid N Protein

Dominance and diversity in the 926 primary human CD4 T cell response to replication-competent vaccinia virus

SARS-CoV-2-specific T cell 929 immunity in cases of COVID-19 and SARS, and uninfected controls

Divergent SARS-CoV-935 2-specific T-and B-cell responses in severe but not mild COVID-19 patients

Broad and strong memory CD4(+) and 938 CD8(+) T cells induced by SARS-CoV-2 in UK convalescent individuals following COVID-19

Comparative host-941 coronavirus protein interaction networks reveal pan-viral disease mechanisms

SARS-CoV-2 proteome microarray for 944 global profiling of COVID-19 specific IgG and IgM responses

SARS-CoV-2 ORF9b inhibits RIG-I-MAVS antiviral 947 signaling by interrupting K63-linked ubiquitination of NEMO

Negligible impact of SARS-CoV-2 949 variants on CD4 (+) and CD8 (+) T cell reactivity in COVID-19 exposed donors and vaccinees. 950 bioRxiv : the preprint server for biology

SARS-CoV-2 952 mutations in MHC-I-restricted epitopes evade CD8(+) T cell responses

Structural Basis for Clonal Diversity of 955 the Public T Cell Response to a Dominant Human Cytomegalovirus Epitope. The Journal of 956 biological chemistry

Immunology in the Clinic Review Series; focus 958 on host responses: T cell responses to herpes simplex viruses

The impact of viral mutations on 963 recognition by SARS-CoV-2 specific T-cells

Prior 965 infection with SARS-CoV-2 boosts and broadens Ad26.COV2.S immunogenicity in a variant-966 dependent manner. Cell host & microbe. 2021. 967 73

Selective and cross-reactive 970 SARS-CoV-2 T cell epitopes in unexposed humans

CoV-2-Seronegative Subjects Target CTL Epitopes in the SARS-CoV-2 Nucleoprotein Cross-974 Reactive to Common Cold Coronaviruses

Low-dose 976 mRNA-1273 COVID-19 vaccine generates durable memory enhanced by cross-reactive T cells

Heterologous humoral immunity to 979 human and zoonotic coronaviruses: Aiming for the achilles heel

982 Seasonal coronavirus-specific B cells with limited SARS-CoV-2 cross-reactivity dominate the IgG 983 response in severe COVID-19

Recent endemic coronavirus 985 infection is associated with less-severe COVID-19

CD8(+) T cells 988 specific for an immunodominant SARS-CoV-2 nucleocapsid epitope display high naive precursor 989 frequency and TCR promiscuity

A large-scale database of T-991 cell receptor beta (TCRbeta) sequences and binding associations from natural and synthetic 992 exposure to SARS-CoV-2

Persistent 994 cellular immunity to SARS-CoV-2 infection

Single-cell RNA sequencing 996 reveals ex vivo signatures of SARS-CoV-2-reactive T cells through 'reverse phenotyping'. Nature 997 communications

Genomic surveillance reveals 999 multiple introductions of SARS-CoV-2 into Northern California

SARS-CoV-2 Serologic Assays 1001 in Control and Unknown Populations Demonstrate the Necessity of Virus Neutralization Testing

Comprehensive 1004 mapping of mutations in the SARS-CoV-2 receptor-binding domain that affect recognition by 1005 polyclonal human plasma antibodies

Complete Mapping of 1007 Mutations to the SARS-CoV-2 Spike Receptor-Binding Domain that Escape Antibody Recognition

7 to mRNA vaccine-elicited antibodies

Global initiative on sharing all influenza data -from vision to 1012 reality. Euro surveillance : bulletin Europeen sur les maladies transmissibles = European 1013 communicable disease bulletin

Molecular Pattern Recognition of Hepatitis C Virus Transmitted/Founder Variants by RIG-I Is 1016 Dependent on U-Core Length

Optimizing high-yield production 1018 of SARS-CoV-2 soluble spike trimers for serology assays. Protein expression and purification

Estimated 1021 transmissibility and impact of SARS-CoV-2 lineage B.1.1.7 in England

Genomic characterization of a novel SARS-CoV-2 lineage from Rio de Janeiro, Brazil

Expression cloning for the discovery of viral antigens and epitopes recognized by T-1027 cells

Coronavirus biology and replication: 1029 implications for SARS-CoV-2

CD8 CTL from genital herpes 1031 simplex lesions: recognition of viral tegument and immediate early proteins and lysis of infected 1032 cutaneous cells

Immortalization of human 1034 bronchial epithelial cells in the absence of viral oncoproteins

CD8 CTL from genital herpes 1036 simplex lesions: recognition of viral tegument and immediate early proteins and lysis of infected 1037 cutaneous cells

Virologic and immunologic 1039 evidence of multifocal genital herpes simplex virus 2 infection

Antigenic 1042 specificity of human CD4+ T cell clones recovered from recurrent genital HSV-2 lesions

Autologous herpes simplex virus-infected cells are lysed by human 1045 natural killer cells

The immune 1047 epitope database (IEDB) 3.0